Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,501.65 -12.72 -0.08%
S&P 500 1,875.39 -4.16 -0.22%
NASDAQ 4,126.97 -34.49 -0.83%
Ticker Volume Price Price Delta
STOXX 50 3,198.48 22.51 0.71%
FTSE 100 6,716.91 42.17 0.63%
DAX 9,609.86 65.67 0.69%
Ticker Volume Price Price Delta
NIKKEI 14,404.99 -141.28 -0.97%
TOPIX 1,164.90 -8.91 -0.76%
HANG SENG 22,562.80 53.16 0.24%

AcelRx Pharmaceuticals to Hold Third Quarter 2013 Financial Results Conference Call and Webcast on November 5, 2013



AcelRx Pharmaceuticals to Hold Third Quarter 2013 Financial Results Conference
                     Call and Webcast on November 5, 2013

PR Newswire

REDWOOD CITY, Calif., Oct. 22, 2013

REDWOOD CITY, Calif., Oct. 22, 2013 /PRNewswire/ -- AcelRx Pharmaceuticals,
Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the
development and commercialization of innovative therapies for the treatment of
acute and breakthrough pain, today announced that it will release third
quarter 2013 financial results after market close on Tuesday, November 5,
2013.  AcelRx management will host an investment-community conference call at
4:30 p.m. eastern time (1:30 p.m. pacific time) on November 5, 2013 to discuss
the financial results and provide a corporate update.

Investors who wish to participate in the conference call may do so by dialing
(877) 870-4263 for domestic callers, (855) 669-9657 for Canadian callers or
(412) 317-0790 for international callers. Those interested in listening to the
conference call live via the internet may do so by visiting the Investors page
of the company's website at www.acelrx.com and clicking on the webcast link on
the Investors home page.

A webcast replay will be available on the AcelRx website for 90 days following
the call by visiting the Investor page of the company's website at
www.acelrx.com.

About AcelRx Pharmaceuticals, Inc.

AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on
the development and commercialization of innovative therapies for the
treatment of acute and breakthrough pain. AcelRx's lead product candidate,
Zalviso™, is designed to solve the problems associated with post-operative
intravenous patient-controlled analgesia which has been shown to cause harm to
patients following surgery because of the side effects of morphine, the
invasive IV route of delivery and the complexity of infusion pumps.  AcelRx
has announced positive results from each of the three Phase 3 clinical trials
completed for Zalviso, and has submitted an NDA to the FDA seeking approval
for Zalviso to be used to treat moderate-to-severe acute pain in the hospital
setting.  AcelRx has also announced positive top-line results for a Phase 2
trial for ARX-04, a product candidate for the treatment of moderate-to-severe
acute pain in a medically supervised setting, funded through a grant from the
U.S. Army Medical Research and Materiel Command.  The company has two
additional pain treatment product candidates, ARX-02 and ARX-03, which have
completed Phase 2 clinical development.  For additional information about
AcelRx's clinical programs, please visit www.acelrx.com.

Forward Looking Statements

This press release contains forward-looking statements, including, but not
limited to, statements related to the Phase 3 clinical trial data for Zalviso
and the therapeutic potential of Zalviso and AcelRx Pharmaceuticals' other
product candidates. These forward-looking statements are based on AcelRx's
current expectations and inherently involve significant risks and
uncertainties.  AcelRx's actual results and the timing of events could differ
materially from those anticipated in such forward-looking statements as a
result of these risks and uncertainties, which include, without limitation,
risks related to: the fact that FDA may not accept for filing the Zalviso NDA;
AcelRx's ability to receive regulatory approval for Zalviso, including whether
the results of the Phase 3 clinical trials for Zalviso are sufficient to
obtain marketing approval for Zalviso, which depends on the ability of AcelRx
to demonstrate to the satisfaction of the FDA the safety and efficacy of
Zalviso based upon its findings of the Phase 3 trials; any delays or inability
to obtain and maintain regulatory approval of its product candidates,
including Zalviso, in the United States and Europe; its ability to attract
funding partners or collaborators with development, regulatory and
commercialization expertise; its ability to obtain sufficient financing to
commercialize Zalviso;  the market potential for its product candidates; and
other risks detailed in the "Risk Factors" and elsewhere in AcelRx's  U.S.
Securities and Exchange Commission filings and reports, including its
Quarterly Report on Form 10-Q filed with the SEC on August 12, 2013.  AcelRx
undertakes no duty or obligation to update any forward-looking statements
contained in this release as a result of new information, future events or
changes in its expectations.

(Logo: http://photos.prnewswire.com/prnh/20130226/MM67303LOGO)

SOURCE AcelRx Pharmaceuticals, Inc.

Website: http://www.acelrx.com
Contact: Jim Welch, Chief Financial Officer, 650.216.3511, jwelch@acelrx.com
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement